Bioavailability Clinical Development In-Vitro In-Vivo 
Pharmaceutical Technology
MAY 31, 2023
It is expected to accelerate the development of CFT8919 in important international markets. CFT8919 is an orally bioavailable BiDAC degrader designed to exhibit potent and selective activity against EGFR L858R in patients with non-small cell lung cancer (NSCLC).
The Pharma Data
OCTOBER 21, 2020
Company is on t rack to s ubmit an IND in the fourth quarter of 2020 and i nitiate a Phase 1 /2 clinical trial for advanced solid tumors in 2021. We designed KB-0742 to be an orally bioavailable CDK9 inhibitor with a differentiated selectivity profile,” said Norbert Bischofberger, Ph.D., SAN MATEO, Calif., and CAMBRIDGE, Mass.,
Expert insights. Personalized for you.
130 
Let's personalize your content